LambdaGen Therapeutics
LambdaGen Therapeutics is dedicated to developing safer and innovative cell and gene therapies, including transformative cancer immunotherapies, leveraging proprietary genome engineering technology called LIGIT. Their mission is to create permanent cures for genetic disorders and advance the field of cell and gene therapy through cutting-edge platform technologies and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
LambdaGen Therapeutics
Clinical Science Building, 11 Mandalay Rd, Singapore 308232
Products
Stable hESC pluripotency reporter cell line (UTF1-based)
A stable human embryonic stem cell line carrying a UTF1-based pluripotency reporter cassette integrated at a defined genomic site for use in differentiation studies and drug screening.
Stem-cell based disease reporter for DUX4 activity
A stem-cell reporter system that expresses a fluorescent reporter upon DUX4 activity, adaptable for high-throughput compound screening for disease-relevant transcriptional modulation.
Mammalian cell line with single-copy artificial docking site (HeLa)
HeLa cell line engineered to carry a single artificial genomic docking site allowing precise targeting of single or multigene constructs for sustained and homogeneous transgene expression without selection pressure.
Expi293 / HEK293 cell line with single-copy artificial docking site
An Expi293 (HEK293) producer cell line containing a single artificial docking site for precise targeting of transgenes, suitable for consistent therapeutic protein production or screening applications.
Stable hESC pluripotency reporter cell line (UTF1-based)
A stable human embryonic stem cell line carrying a UTF1-based pluripotency reporter cassette integrated at a defined genomic site for use in differentiation studies and drug screening.
Stem-cell based disease reporter for DUX4 activity
A stem-cell reporter system that expresses a fluorescent reporter upon DUX4 activity, adaptable for high-throughput compound screening for disease-relevant transcriptional modulation.
Mammalian cell line with single-copy artificial docking site (HeLa)
HeLa cell line engineered to carry a single artificial genomic docking site allowing precise targeting of single or multigene constructs for sustained and homogeneous transgene expression without selection pressure.
Expi293 / HEK293 cell line with single-copy artificial docking site
An Expi293 (HEK293) producer cell line containing a single artificial docking site for precise targeting of transgenes, suitable for consistent therapeutic protein production or screening applications.
Services
Contract engineering of mammalian cell lines using integrase-mediated site-specific integration to insert large transgene constructs (>10 kb) and generate stable single-copy integrations for research or production use.
Small- and large-scale production pipeline for seamless supercoiled DNA vectors across a broad size range, offered as in-house manufacturing or as a licensable production process.
Design and generation of mammalian producer and master cell lines with artificial docking sites for reproducible therapeutic protein expression and screening applications.
Platform-enabled genetic modification of marine microalgae to create stable expression of recombinant proteins from genomic docking sites for cell bioreactor applications.
Preclinical testing and evaluation workflows for encapsulated, immuno-protected producer cell implants in animal cancer models to assess viability, fibrosis, tumor response and therapeutic protein output.
Contract engineering of mammalian cell lines using integrase-mediated site-specific integration to insert large transgene constructs (>10 kb) and generate stable single-copy integrations for research or production use.
Small- and large-scale production pipeline for seamless supercoiled DNA vectors across a broad size range, offered as in-house manufacturing or as a licensable production process.
Design and generation of mammalian producer and master cell lines with artificial docking sites for reproducible therapeutic protein expression and screening applications.
Platform-enabled genetic modification of marine microalgae to create stable expression of recombinant proteins from genomic docking sites for cell bioreactor applications.
Preclinical testing and evaluation workflows for encapsulated, immuno-protected producer cell implants in animal cancer models to assess viability, fibrosis, tumor response and therapeutic protein output.
Expertise Areas
- Site-specific genome integration
- Cell line engineering and master cell-line development
- iPSC-derived cell therapy development (CAR-NK)
- Seamless DNA/minicircle vector production
Key Technologies
- Site-specific recombinase-mediated insertion
- Non-viral circular DNA vectors / minicircles
- Engineered E. coli production strains
- Genome landing-pad / docking-site systems
News & Updates
Chaudhari N, Rickard AM, Roy S, Dröge P, Makhija H. published a study on a non-viral genome editing platform for site-specific insertion of large transgenes.
Roy S, Peter S, Dröge P. described a method for seamless DNA vector production in E. coli using enhanced lambda integrase.
Patent filed in 2022 by NTU & LambdaGen for a platform enabling transgenesis in human cells using enhanced λ integrases.
Patent filed in 2022 by NTU & A*STAR for sequence-specific transgenesis at a human safe harbor site.
Chaudhari N, Rickard AM, Roy S, Dröge P, Makhija H. published a study on a non-viral genome editing platform for site-specific insertion of large transgenes.
Roy S, Peter S, Dröge P. described a method for seamless DNA vector production in E. coli using enhanced lambda integrase.
Patent filed in 2022 by NTU & LambdaGen for a platform enabling transgenesis in human cells using enhanced λ integrases.
Patent filed in 2022 by NTU & A*STAR for sequence-specific transgenesis at a human safe harbor site.